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Objectives The present study sought to evaluate the clinical utility of pro-B-type natriuretic peptides (proBNP) in patients
admitted with acute decompensated heart failure.
Background Plasma natriuretic peptides (BNP1–32, N-terminal [NT]-proBNP1–76) have been demonstrated to assist in the diag-
nosis of patients with heart failure. However, the precursor to these polypeptides (proBNP1–108) circulates in
plasma and may interfere with the measurement of currently used biomarkers.
Methods Plasma natriuretic peptides were assessed in 164 individuals (99% men) hospitalized with decompensated
heart failure. The B-type natriuretic peptide (BNP), NT-proBNP, and proBNP levels at hospital admission and dis-
charge were compared with the incidence of cardiac death and all-cause mortality within 90 days post-
discharge.
Results Pro-B-type natriuretic peptides demonstrated a high degree of correlation with both BNP (R  0.924, p  0.001)
and NT-proBNP (R  0.802, p  0.001) at admission. Further characterization of proBNP demonstrated little
variation with changes in age, body mass index, creatinine, or systolic dysfunction. All 3 plasma natriuretic pep-
tides were significantly elevated at admission in patients suffering a cardiac death or all-cause mortality (p 
0.05). Receiver-operating characteristic curves demonstrated that admission and discharge NT-proBNP (area
under the curve [AUC] 0.788 and AUC 0.834) had superior prognostic power for all-cause mortality when com-
pared with BNP (AUC 0.644, p  0.01 and AUC 0.709, p  0.01) and proBNP (AUC 0.653, p  0.01 and AUC
0.666, p  0.01) at the same time points.
Conclusions Admission values of all natriuretic peptides can be used to predict cardiac death and all-cause mortality. A pre-
liminary comparison suggests that discharge values of NT-proBNP have the greatest diagnostic yield for predict-
ing these end points. Further studies should explore the synergistic prognostic potential of all natriuretic
peptides. (J Am Coll Cardiol 2008;51:1874–82) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.051i
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mongestive heart failure is the leading cause of hospital
dmission among patients over the age of 65 years (1). Five
ercent of the total national health care budget is spent on
he treatment and hospitalization of patients suffering from
eart failure (1). Despite advances in treatment modalities,
atients admitted with decompensated heart failure have
ignificant hospital mortality and considerable readmission
ates (2). The lack of an effective method to assess treatment
fficacy in heart failure patients may contribute to these
roblems. A simple diagnostic protocol capable of measur-
rom the *University of California at San Diego, Veterans Affairs San Diego
ealthcare System, San Diego, California; †University of California at San Diego
chool of Medicine, San Diego, California; and the ‡CNRS FRE3009, Faculty of
harmacy, Montpellier, France. Margaret Redfield, MD, served as Guest Editor for
his article.p
Manuscript received April 10, 2007; revised manuscript received December 10,
007, accepted December 11, 2007.ng inpatient treatment efficacy would be invaluable in
uiding clinical decision making.
B-type natriuretic peptide (BNP) is a cardiac hormone
ecreted from membrane granules of the ventricles in
esponse to volume expansion and pressure overload (3).
nlike other natriuretic peptides, the precursor to BNP is
ranslated from an inherently unstable messenger ribonu-
leic acid (mRNA) sequence containing the bases TATT-
AT (4). The inherent instability of the BNP precursor
equence leads to the rapid turnover of its mRNA resulting in
ursts of peptide release temporally corresponding to increases
n ventricular volume and pressure (5). The expression and
ranslation of the BNP precursor sequence results in a 134-
mino-acid peptide denoted as preproBNP that is subse-
uently cleaved to a 108-amino-acid sequence denoted as
roBNP1–108 (3,6). Further proteolytic processing cleaves a
ature 32-amino-acid peptide from pro-B-type natriureticeptides (proBNPs), designated BNP1–32, that produces vaso-
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May 13, 2008:1874–82 ProBNP in Decompensated HFilation and increased urinary salt clearance (6). The
-terminal peptide fragment (NT-proBNP1–76) released from
his proteolytic modification also circulates in plasma without
nown physiological activity (3). Research suggests that each of
hese peptides can be used in the evaluation of patients with
eart failure.
A number of studies have demonstrated the clinical utility
f natriuretic peptides in the diagnosis and treatment of
eart failure. Initial work demonstrated that circulating
NP levels correspond to pulmonary capillary wedge pres-
ure and clinical symptoms measured by the New York
eart Association functional classification (7,8). Subse-
uent research has proven that changes in BNP levels
uring inpatient treatment are strong predictors for subse-
uent hospitalization and eventual mortality (9,10). The
T-proBNP, like its active analogue BNP, can also aid in
he diagnosis of heart failure in asymptomatic patients
resenting with acute dyspnea (11). Research has suggested
hat NT-proBNP levels during hospitalization are strong
redictors for hospital readmission and mortality (12,13).
he utility of NT-proBNP in predicting subsequent cardiac
vents has been confirmed in patients with renal insuffi-
iency in spite of its renal clearance (14,15). Despite the
ntensive investigations of BNP and NT-proBNP in heart
ailure patients, little data have been presented regarding
ther natriuretic peptide metabolites or precursor compounds.
Research has demonstrated that the intact precursor to
oth BNP and NT-proBNP circulates in the blood stream
f patients with heart failure (16). Some have suggested that
urrent assays for both BNP and NT-proBNP may be
nfluenced by the presence of proBNP in serum (17). This
as prompted the development of a specific assay for
roBNP (18). However, prospective studies evaluating the
linical utility of proBNP have not yet been performed. The
resent study characterizes proBNP in patients hospitalized
ith acute decompensated heart failure.
ethods
opulation. The study design was reviewed and approved
y the University of California at San Diego Institutional
eview Board. Patients admitted to the San Diego Veterans
ffairs Medical Center with a clinical diagnosis of acute
ecompensated heart failure between July 2002 and Decem-
er 2005 were eligible for enrollment in the study and
nclusion in the Veterans’ Administration Effective Therapy
ohort. Patients under the age of 18 years or unable to
rovide informed consent were excluded from participation.
f the eligible patients, 192 unique individuals agreed to
articipate, and 164 individuals provided sufficient blood
amples for analysis of all natriuretic peptides. A sufficient
lood sample was defined as a volume sufficient for bio-
hemical analysis within 24 h of hospital admission and a
eparate sample within 24 h of in-hospital death or dis-
harge. After obtaining written informed consent, data were
btained from verbal conversations with the patient and a peview of the electronic medical
ecord. Blood samples from ve-
ipuncture were immediately
rozen and stored at admission
nd during each subsequent hos-
ital day until discharge for fur-
her analysis. After discharge
rom the hospital, the patient
as re-evaluated through a re-
iew of the electronic medical
ecord or via telephone conversa-
ion to evaluate for the primary
nd secondary end points. The
re-specified primary end point
as cardiac death within 90 days
ost-discharge. The secondary end point was all-cause
ortality during the same follow-up period. In-hospital
ortality was considered a death on the day of discharge.
or comparison, proBNP levels were also assessed in a
roup of 50 normal male volunteers (age 54  3 years)
ithout known cardiac disease.
iochemical assays. Approximately 5 ml of blood from
enipuncture was collected into a tube containing potassium
thylenediamine tetra-acetic acid (1 mg/ml) at each time
oint. The samples were subsequently frozen at70°C until
urther analysis without undergoing any additional freeze–
haw cycles. B-type natriuretic peptide was measured using
he Triage B-Type Natriuretic Peptide Assay (Biosite, San
iego, California) as previously described (19,20). The
T-proBNP was assessed using the Elecsys ProBNP assay
Roche Diagnostics, Indianapolis, Indiana) as outlined in
rior publications (20,21). It is important to note that
urrent assays for BNP and NT-proBNP do not use
pecific antibodies against the cleavage products and thus
ecognize both the proBNP precursor as well as their
ntended target (22,23).
Pro-B-type natriuretic peptide was determined using an
mproved version of the Bio-Rad proBNP assay (Research
se Only, Bio-Rad, Hercules, California) initially described
y Giuliani et al. (18). This assay utilizes an immobilized
ntibody targeted toward the hinge region (residues 75 to
0) of the proBNP precursor that is not present on
ubsequent natriuretic peptides. Consequently, there is min-
mal cross reactivity (1.5%) of this assay with BNP and
T-proBNP. The method described by Giuliani et al. (18)
as improved in the present study by using a monoclonal
urine secondary antibody specifically targeting the BNP
ing, resulting in a significant reduction in background
ignal. This proBNP assay is characterized by excellent
inearity with recombinant proBNP (Hytest Ltd., Turku,
inland) with concentrations ranging from 10 to 10,000
g/l. The detection limit, calculated as the mean  3
tandard deviations, was computed as 4 ng/l with an
ntra-assay coefficient of variation of 5%.
tatistics. The correlation of natriuretic peptides was com-
Abbreviations
and Acronyms
AUC  area under the
curve
BMI  body mass index
BNP  B-type natriuretic
peptide
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
proBNP  pro-B-type
natriuretic peptide
ROC  receiver-operating
characteristicuted with a Spearman correlation coefficient. Box and
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ProBNP in Decompensated HF May 13, 2008:1874–82hisker plots were created such that a box contained the
5th to 75th percentiles and the whiskers contained the
0th to 90th percentiles. Mann-Whitney U tests were
tilized to determine statistical differences in natriuretic
eptides among patients reaching the primary or secondary
nd point. These statistics were computed using SPSS
tatistical software (SPSS Inc., Chicago, Illinois). Receiver-
perating characteristic (ROC) curves were created to iden-
ify the prognostic utility of each assay. Statistical compar-
sons of the area under the curves (AUCs) were computed
ased on a previously described model using SAS statistical
emographic Data
Table 1 Demographic Data
n %
Age (yrs) 68  13
Gender
Male 162 99
Female 2 1
Race
Caucasian 124 76
African American 24 15
Hispanic 12 7
Other 4 3
Past medical history
Hypertension 123 75
Coronary artery disease 104 63
Diabetes 87 53
Myocardial infarction 59 36
Atrial fibrillation 58 35
Chronic renal insufficiency 49 30
Chronic obstructive pulmonary disease 44 27
Admission diagnosis
Congestive heart failure (exacerbation) 118 72
Congestive heart failure (new onset) 17 10
NYHA functional classification 3.4  0.6
Admission etiology
Ischemic 107 65
Hypertensive 34 21
Idiopathic 9 5
Alcohol abuse 6 4
Valvular 4 2
Admission medications
Diuretic 109 66
Beta-blocker 85 52
ACE inhibitor 82 50
Digoxin 38 23
Calcium-channel blocker 34 21
Angiotensin receptor blocker 16 10
Spironolactone 11 7
Admission vitals
Weight (lbs) 212  56
Systolic blood pressure 135  26
Diastolic blood pressure 74  19
Admission labs
Serum sodium (mEq) 138  4
Serum creatinine (mg/dl) 1.7  1.0(CE  angiotensin-converting enzyme; NYHA  New York Heart Association.oftware (SAS Institute, Cary, North Carolina) (24). For all
omparisons, a p value 0.05 was considered statistically
ignificant.
esults
emographic data. The demographic characteristics of
he 164 patients that provided blood samples for all natri-
retic peptide analyses are summarized in Table 1. The
ajority of participants were men (99%) with a predomi-
ance of ischemic cardiomyopathy (65%). In accordance
ith the study inclusion criteria, these patients were hospi-
alized with a median New York Heart Association func-
ional classification of III. The majority of participants were
lso previously diagnosed with significant comorbid condi-
ions including hypertension (75%), coronary artery disease
Figure 1 Natriuretic Peptide Correlation
Plasma natriuretic peptides were assessed in 164 unique individuals admitted
for decompensated congestive heart failure. The scatter plots above demon-
strate that pro-B-type natriuretic peptide (proBNP) at admission is highly corre-
lated with both B-type natriuretic peptide (R  0.924, p  0.001) and
N-terminal pro-B-type natriuretic peptide (NT-proBNP) (R  0.802, p  0.001)
at the same time point. This correlation was consistent at all time points
assessed during a mean hospital stay of 5.5  7.1 days (data not shown).63%), and diabetes mellitus (53%).
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May 13, 2008:1874–82 ProBNP in Decompensated HFatriuretic peptide correlation. The correlation between
atriuretic peptides was calculated from a total of 539
amples taken from 164 unique individuals over an average
f 5.5  7.1 hospital days. As a representative example,
igure 1 summarizes the correlation for each pair of
atriuretic peptides at admission. The measurements of
roBNP demonstrate a high correlation with both BNP
R  0.924, p  0.001) and NT-proBNP (R  0.802, p 
.001) at this time point. This high degree of correlation
as consistent at all time points assessed throughout hos-
italization (data not shown).
atriuretic peptide characterization. The admission val-
es of natriuretic peptides were compared with the charac-
eristics of the 164 unique individuals hospitalized for heart
ailure. Figures 2A and 2B demonstrate that proBNP is
ndependent of age and body mass index (BMI). As shown
n Figure 2C, proBNP levels are also independent of serum
reatinine and corresponding renal insufficiency. Figure 2D
emonstrates that proBNP levels are similar in patients with
ystolic or diastolic dysfunction as determined by transtho-
acic echocardiography. It is important to note that BNP
nd NT-proBNP were also not affected by these parameters
n our limited patient population (data not shown). For
Figure 2 Natriuretic Peptide Characterization
Plasma B-type natriuretic peptides were compared with the characteristics of the 164
plots in A and B demonstrate that pro-B-type natriuretic peptide (proBNP) is independ
pendent of serum creatinine and corresponding renal insufficiency. Panel D demonstromparison, a group of 50 normal male volunteers without
nown cardiac disease age 54 3 years had a mean proBNP
evel of 223  570 pg/ml.
atriuretic peptides and cardiac death. The plasma na-
riuretic peptide levels at admission and discharge were
ompared among the 13 patients that met the primary end
oint. As shown in Figure 3A, all 3 natriuretic peptides
ere significantly increased at admission in patients that
uffered a cardiac death within 90 days of hospital discharge
p  0.05). As shown in Figure 3B, patients with a cardiac
eath had a decrease in proBNP levels during their hospital
ourse that made the discharge value statistically similar to
atients without a subsequent cardiac death (p 0.13). The
evel of decline in proBNP during hospitalization had little
elation to ultimate events.
atriuretic peptides and all-cause mortality. The plasma
atriuretic peptide levels obtained at admission and dis-
harge were compared among the 22 patients that met the
econdary end point. As shown in Figure 4A, all 3 natri-
retic peptides were significantly increased at admission in
atients that suffered all-cause mortality within 90 days of
ospital discharge (p  0.05). Figure 4B demonstrates that
hese peptides were also significantly increased at discharge
individuals hospitalized for congestive heart failure (CHF). The box and whisker
age and body mass index (BMI). Panel C suggests that proBNP levels are also inde-
at proBNP levels are unchanged in patients with systolic or diastolic dysfunction.unique
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ProBNP in Decompensated HF May 13, 2008:1874–82n patients that met the secondary end point (p  0.05).
nce again, changes in levels during hospitalization had no
earing on ultimate outcomes.
atriuretic peptides and prognosis. The differences in
dmission levels of proBNP among the patients that met
he primary or secondary end point prompted investigation
f absolute proBNP values that could be used for prognosis.
he plasma levels of proBNP at admission were thus
ivided into tertiles and compared with the incidence of the
rimary and secondary end points. Figure 5A demonstrates
hat patients admitted with a proBNP level less than 1,400
g/ml regardless of BNP level had significantly fewer
ardiac deaths (n  0) within the follow-up period than
hose with an admission proBNP value of 1,400 to 4,550
g/ml (p  0.05) or 4,550 pg/ml (p  0.001). Figure 4B
emonstrates that patients admitted with a proBNP level
1,400 pg/ml had significantly fewer all-cause deaths (n 
Figure 3 Natriuretic Peptides and Cardiac Death
Admission and discharge plasma natriuretic peptide levels were evaluated in
patients that met the primary end point. The box and whisker plots in A dem-
onstrate that patients that suffered a cardiac death (gray boxes) had signifi-
cantly higher plasma natriuretic peptide levels at admission compared with
those that did not have an event (open boxes) within 90 days of hospital dis-
charge. Panel B demonstrates that B-type natriuretic peptide (BNP) and
N-terminal pro-B-type natriuretic peptides (NT-proBNP) levels were also signifi-
cantly elevated at discharge in patients suffering a cardiac death (gray boxes)
when compared with those that did not (open boxes).) within the follow-up period than those with an admissionroBNP value4,550 pg/ml (p 0.05). The middle tertile
f admission proBNP levels (1,400 to 4,550 pg/ml) did not
ave a significantly different outcome from the other tertiles
n terms of all-cause mortality.
omparing natriuretic peptides for cardiac death prog-
osis. The admission and discharge values of the natri-
retic peptides were compared for their ability to predict the
ncidence of the primary end point. A series of ROC curves
ere created for each of the natriuretic peptides at admis-
ion and discharge as related to the incidence of cardiac
eath (Fig. 6A). Each natriuretic peptide at admission
emonstrated an AUC exceeding 0.71 that statistically
iffered from the null hypothesis (p  0.02). The AUC
or predicting cardiac death was not statistically different
mong the natriuretic peptides at admission. At dis-
harge, BNP and NT-proBNP demonstrated an AUC
xceeding 0.73 that statistically differed from the null
ypothesis (p  0.01). A statistical comparison of the
Figure 4 Natriuretic Peptides and All-Cause Mortality
Admission and discharge proBNP levels were evaluated in patients that met
the secondary end point. The box and whisker plots in A demonstrate that
patients that suffered all-cause mortality (gray boxes) within 90 days of hospi-
tal discharge had significantly higher natriuretic peptide levels at admission
compared with those that survived (open boxes). Panel B demonstrates that
all 3 natriuretic peptides were also significantly elevated at discharge in
patients suffering all-cause mortality (gray boxes) when compared with those
that did not meet the secondary end point (open boxes). BNP  B-type natri-
uretic peptide; other abbreviations as in Figure 1.
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May 13, 2008:1874–82 ProBNP in Decompensated HFUC suggests that NT-proBNP and BNP at discharge
as superior prognostic power for cardiac death compared
ith proBNP (p  0.05). As shown in the figure, the
hange in all natriuretic peptides during hospitalization
id not predict outcome.
omparing natriuretic peptides for all-cause mortality
rognosis. The admission and discharge values of the
atriuretic peptides were compared for their ability to
redict the incidence of the secondary end point. A series of
OC curves were created for each of the natriuretic pep-
ides at admission and discharge as related to all-cause
ortality (Fig. 6B). All natriuretic peptides at admission
xhibited an AUC exceeding 0.64 that statistically differed
rom the null hypothesis (p  0.05). Comparison of the
UC demonstrated that admission values of NT-proBNP
Figure 5 Natriuretic Peptides and Prognosis
The plasma natriuretic peptide levels at admission were divided into tertiles
and compared with the primary and secondary end points. The Kaplan-Meyer
curve in panel A demonstrates that patients admitted with a pro-B-type natri-
uretic peptide (proBNP) level 1,400 pg/ml had significantly fewer cardiac
deaths compared with patients in the other tertiles within the follow-up period
(p  0.05). Panel B demonstrates that patients admitted with a proBNP level
1,400 pg/ml had significantly fewer all-cause deaths within the follow-up
period than those with an admission proBNP value 4,550 pg/ml (p  0.05).ad significantly greater prognostic power for all-cause oortality when compared with BNP (p  0.01) and
roBNP (p  0.01). At discharge, each natriuretic peptide
emonstrated an AUC exceeding 0.66 that statistically
iffered from the null hypothesis (p  0.02).
Comparison of the AUC demonstrated that discharge
alues of NT-proBNP had significantly greater prognostic
ower for all-cause mortality when compared with BNP
p  0.01) and proBNP (p  0.01). The percent change in
NP during hospitalization produced an AUC of 0.64 (p
.05). Thus, the admission and discharge values of NT-
roBNP had superior prognostic power for all-cause mor-
ality when compared with the other natriuretic peptides
ssessed at the same time point.
iscussion
ongestive heart failure is a leading cause of morbidity and
ortality with significant rates of treatment failure. Research
as demonstrated that metabolites of natriuretic peptides may
ssist in the diagnosis and treatment of this disease. Numerous
tudies have demonstrated that BNP and NT-proBNP are
apable of predicting hospital readmission and eventual mor-
ality in patients suffering from heart failure (9,10,12–14,25).
owever, it is now apparent that the current assays for both
NP and NT-proBNP may be influenced by other circulating
orms of BNP (17). This hypothesis is supported by recent
ork utilizing mass spectroscopy that failed to identify any
irculating BNP in patients with class IV heart failure despite
ignificant elevations on point-of-care BNP testing (26). The
resent study provides the first prospective evaluation of
roBNP in patients hospitalized with acute decompensated
eart failure.
The initial characterization of proBNP in the present
tudy suggests that it has significantly different pharmaco-
inetics from its cleavage products. Previous work has
uggested that BNP and NT-proBNP levels increase with
ge even after excluding patients with “age-related diastolic
ysfunction” (27,28). In the present study, our data indicate
imilar proBNP levels in heart failure patients throughout
ll age groups. Previous research has also demonstrated that
NP and NT-proBNP levels are inversely related to obesity
29–32). Investigators have hypothesized that there may be
BMI-related defect in natriuretic peptide secretion (29).
n the present study, measurements of proBNP were con-
istent across all degrees of obesity suggesting that the
ecretion is constant but the subsequent metabolism of the
atriuretic peptides may be altered in the setting of in-
reased BMI. Additional studies have suggested that both
NP and NT-proBNP levels are elevated in patients with
nd-stage renal disease (15,25). The present study demon-
trates that proBNP levels are not significantly elevated in
eart failure patients with renal insufficiency possibly sug-
esting a more accurate representation of isolated cardiac
ysfunction. It is important to note that others have
bserved differences in proBNP levels with regard to age,
besity, and renal function among nonhospitalized patients
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ProBNP in Decompensated HF May 13, 2008:1874–8233). The different findings in the present study may be
elated to our relatively selective patient population. Re-
ardless, the pharmacokinetics of proBNP may have impli-
ations for its clinical utility.
The present study confirms the role of natriuretic pep-
ides in the diagnosis and treatment of congestive heart
ailure. These findings parallel studies that suggest that
lasma BNP and NT-proBNP levels are independent pre-
ictors of cardiovascular events in populations with heart
ailure or acute coronary syndromes (9,10,12–14,25,34,35).
he precursor to these natriuretic peptides, proBNP, also
emonstrated clinical utility with significantly elevated lev-
ls at admission in patients ultimately suffering a cardiac
eath or all-cause mortality. The present data suggest that
n admission proBNP level 1,400 pg/ml regardless of
Figure 6 Natriuretic Peptides and Prognosis of All-Cause Morta
The admission and discharge natriuretic peptides were assessed for their ability to
summarizes the relationship between all natriuretic peptides and cardiac death. A
est prognostic potential (p  0.05). Panel B summarizes the relationship between
values of NT-proBNP had the greatest prognostic potential (p  0.01). AUC  area
abbreviations as in Figure 1.NP level predicts excellent outcomes. The utility of this nnding is particularly important in patients with “gray-
one” BNP levels (100 to 500 pg/ml). Dyspneic patients in
he emergency department with “gray-zone” BNP levels
ave better outcomes than those with BNP levels above the
gray zone,” despite being perceived as having more severe
ecompensation (36). If the results of the present study are
alidated in other patient populations, patients presenting to
he emergency department with proBNP levels under 1,400
g/ml would be considered to be at very low risk. Further
tudies powered to detect this interaction with larger patient
ohorts should evaluate the ability of proBNP to triage
atients in combination with existing biomarkers.
The prognostic potential of proBNP may reflect its role
n the pathophysiology of decompensated heart failure. A
umber of studies now suggest that the major circulating
ict the incidence of the primary end point and secondary end points. Panel A
onstrated in the figure, discharge values of NT-proBNP and proBNP had the great-
retic peptides and all-cause mortality. Once again, the admission and discharge
r the curve; BNP  B-type natriuretic peptide; CI  confidence interval; otherlity
pred
s dem
natriu
undeatriuretic peptide in patients with decompensated heart
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May 13, 2008:1874–82 ProBNP in Decompensated HFailure is proBNP (22,26). However, proBNP has been
emonstrated to have significantly lower biological activity
han its active metabolite BNP (22). Because of this, there
ay be discordance between the high level of circulating
atriuretic peptide metabolites and their physiological ac-
ivity, thus resulting in a functional deficiency in the
ecompensated state. Some have suggested that a further
nvestigation into the biochemistry behind natriuretic pep-
ide metabolism may provide insight into this paradox
37,38). Unfortunately, available assays for BNP and NT-
roBNP also detect proBNP, making it impossible to
urrently construct meaningful ratios of the known natri-
retic peptides. Elucidating the role of the individual
atriuretic peptides in the neuroendocrine mechanisms of
ecompensated heart failure will aid in prognosis.
The present study sought to provide an initial comparison
f the prognostic potential of the available natriuretic
eptides. The data presented suggest that discharge values
f NT-proBNP have the greatest diagnostic yield in pre-
icting patients that will suffer a cardiac death or all-cause
ortality within the follow-up period. In concordance with
his finding, pilot studies that utilize serial measurements of
T-proBNP to guide management in heart failure patients
ave demonstrated fewer cardiovascular events (39). Large
linical trials assessing NT-proBNP for monitoring treat-
ent efficacy are currently underway (40). Previous studies
ave suggested that the ability of NT-proBNP to predict
ll-cause mortality may be related to its association with
enal disease and the resulting cardiorenal syndrome (25).
urther studies may illuminate the molecular mechanisms
ccounting for increased NT-proBNP in excess of other
atriuretic peptides in patients eventually suffering cardiac
eath and all-cause mortality. Perhaps, more importantly,
dditional studies with larger patient cohorts producing
reater statistical power could explore the synergistic poten-
ial of combining existing natriuretic peptides with the
roven benefit of proBNP measurement.
tudy limitations. The present study is hindered by a few
navoidable limitations. The number of patients in the
tudy population was relatively small, making some com-
arisons difficult without adequate statistical power. The
tudy population was a convenience sample recruited from a
ingle Veterans’ Administration Medical Center with a
redominantly male patient base. This population also had
high incidence of cardiac disease with other significant
omorbidities. Because of this, the results presented may not
e applicable to other community settings. Assessment for
ubsequent cardiac events was largely performed on the
lectronic medical record. Because of this, it is possible that
ertain events were not included in our analysis. However,
he number of events missed is likely to be negligible, as all
tudy participants have primary care physicians within the
eterans’ Administration Medical Center system and most
btain their care solely through the same center. It is
mportant to note that all of the events recorded from
elephone follow-up were consistent with the electronicedical record. Despite these limitations, though, the
resent study does provide the first prospective evidence for
he clinical utility of proBNP in patients hospitalized with
ongestive heart failure.
onclusions
ur findings provide an initial characterization of proBNP
n patients admitted with acute decompensated heart fail-
re. Furthermore, these data demonstrate that all 3 natri-
retic peptides are significantly increased at hospital admis-
ion in patients ultimately suffering a cardiac death or
ll-cause mortality. An initial comparison of the natriuretic
eptides suggests that discharge values of NT-proBNP have
he greatest collective prognostic utility for reaching these
nd points. It is possible, though, that the assay for
T-proBNP cross reacts with proBNP mitigating some
f its benefit. Further studies with larger cohorts produc-
ng greater statistical power should explore the role of
ombining natriuretic peptides to enhance their prognostic
otential.
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